ArticleAge and ageing2024
Epigenetic age acceleration and the risk of frailty, and persistent activities of daily living (ADL) disability.
Article in Age and ageing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epigenetic Age Acceleration as a Modifiable Public Health Target: A Systematic Review and Meta-Analysis of Environmental, Behavioral, and Social Determinants with Development of the MEAB-Index.International journal of molecular sciences · 2026Pooled it
- Associations of epigenetic age acceleration with motor impairment: Evidence from the Parkinson's Progression Markers Initiative cohort.Neurobiology of aging · 2026Article
- A machine learning approach to identify key epigenetic transcripts for ageing research in human blood (Epitage).Biogerontology · 2026Article
- Biological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.Aging clinical and experimental research · 2026Article
- Accelerated Epigenetic and Inflammatory Aging and Intrinsic Capacity.JAMA network open · 2026Article
- COASI and Musculoskeletal Biological Age: From Biomarker Burden to Clinical Validation.Geriatrics & gerontology international · 2026Article
- Transitions From Frailty States to Cardiovascular Events: An 11-Year Prospective Study of Community-Dwelling Older People.The Canadian journal of cardiology · 2026Article
- The association between sarcopenia and frailty in older adults: a moderated mediation model.BMC geriatrics · 2026Article
- Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.npj aging · 2026Article
- Article
- Maternal adverse childhood experiences and epigenetic aging in pediatric populations: a scoping review.Frontiers in child and adolescent psychiatry · 2026Review
- Associations of Epigenetic Age Acceleration with Motor Impairment: Evidence from the PPMI Cohort.medRxiv : the preprint server for health sciences · 2025Article
- Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.Research square · 2025Article
- Article
- First-generation versus next-generation epigenetic aging clocks: Differences in performance and utility.Biogerontology · 2025Review
- Lack of association between chronological age and fisher group and poor outcomes in older patients with severe-grade aneurysmal subarachnoid hemorrhage: a nationwide registry study in Japan.Neurosurgical review · 2025Article
- Association of frailty and serum neurofilament light chain levels: the mediating role of estimated glomerular filtration rate.Frontiers in aging neuroscience · 2024Article
- Epigenetic age acceleration and cognitive performance over time in older adults.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEpigenetic ageing is among the most promising ageing biomarkers and may be a useful marker of physical function decline, beyond chronological age. This study investigated whether epigenetic age acceleration (AA) is associated with the change in frailty scores over 7 years and the 7-year risk of incident frailty and persistent Activities of Daily Living (ADL) disability among 560 Australians (50.7% females) aged ≥70 years.
methodsSeven AA indices, including GrimAge, GrimAge2, FitAge and DunedinPACE, were estimated from baseline peripheral-blood DNA-methylation. Frailty was assessed using both the 67-item deficit-accumulation frailty index (FI) and Fried phenotype (Fried). Persistent ADL disability was defined as loss of ability to perform one or more basic ADLs for at least 6 months. Linear mixed models and Cox proportional-hazard regression models were used as appropriate.
resultsAccelerated GrimAge, GrimAge2, FitAge and DunedinPACE at baseline were associated with increasing FI scores per year (adjusted-Beta ranged from 0.0015 to 0.0021, P < 0.05), and accelerated GrimAge and GrimAge2 were associated with an increased risk of incident FI-defined frailty (adjusted-HRs 1.43 and 1.39, respectively, P < 0.05). The association between DunedinPACE and the change in FI scores was stronger in females (adjusted-Beta 0.0029, P 0.001 than in males (adjusted-Beta 0.0002, P 0.81). DunedinPACE, but not the other AA measures, was also associated with worsening Fried scores (adjusted-Beta 0.0175, P 0.04). No associations were observed with persistent ADL disability.
conclusionEpigenetic AA in later life is associated with increasing frailty scores per year and the risk of incident FI-defined frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.